Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: Implications for country-wide implementation

Introduction HIV continues to be a major health concern with approximately 2.1 million new infections occurring worldwide in 2015. In Central America, Guatemala had the highest incident number of HIV infections (3,700) in 2015. Antiretroviral pre-exposure prophylaxis (PrEP) was recently recommended by the World Health Organization (WHO) as an efficacious intervention to prevent HIV transmission. PrEP implementation efforts are underway in Guatemala and success will require providers that are knowledgeable and willing to prescribe PrEP. We sought to explore current PrEP awareness and prescribing attitudes among Guatemalan physicians in order to inform future PrEP implementation efforts. Methods We conducted a cross-sectional survey of adult internal medicine physicians at the main teaching hospital in Guatemala City in March 2015. The survey included demographics, medical specialty, years of HIV patient care, PrEP awareness, willingness to prescribe PrEP, previous experience with post-exposure prophylaxis, and concerns about PrEP. The primary outcome was willingness to prescribe PrEP, which was assessed using a 5-point Likert scale for different at-risk population scenarios. Univariate and multivariate logistic regression was performed to identify predictors for willingness to prescribe PrEP. Results Eighty-seven physicians completed the survey; 66% were male, 64% were internal medicine residency trainees, and 10% were infectious disease (ID) specialists. Sixty-nine percent of physicians were PrEP aware, of which 9% had previously prescribed PrEP. Most (87%) of respondents were willing to prescribe PrEP to men who have sex with men (MSM), sex workers, injection drug users, or HIV-uninfected persons having known HIV-positive sexual partners. Concerns regarding PrEP included development of resistance (92%), risk compensation (90%), and cost (64%). Univariate logistic regression showed that younger age, being a resident trainee, and being a non-ID specialist were significant predictors for willingness to prescribe PrEP. In multivariate logistic regression, being a non-ID specialist was a significant predictor. Conclusions Guatemalan physicians at an urban public hospital were PrEP aware and willing to prescribe, but few have actually done so yet. Future education programs should address the concerns identified, including the low potential for the development of antiretroviral resistance. These findings can aid PrEP implementation efforts in Guatemala.

[1]  R. Gandhi Preexposure Prophylaxis for the Prevention of HIV , 2018 .

[2]  Ashley J. Mayo,et al.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. , 2016, The New England journal of medicine.

[3]  Jennifer F Hoy,et al.  Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. , 2016, JAMA.

[4]  A. van der Straten,et al.  Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa , 2016, PloS one.

[5]  Sheena McCormack,et al.  Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial , 2016, The Lancet.

[6]  M. Mimiaga,et al.  Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities , 2016, Journal of the International AIDS Society.

[7]  N. Kilonzo,et al.  The preexposure prophylaxis revolution; from clinical trials to programmatic implementation , 2016, Current opinion in HIV and AIDS.

[8]  David Thompson,et al.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.

[9]  Venkatesan Chakrapani,et al.  Acceptability of HIV Pre-Exposure Prophylaxis (PrEP) and Implementation Challenges Among Men Who Have Sex with Men in India: A Qualitative Investigation. , 2015, AIDS patient care and STDs.

[10]  J. Auerbach,et al.  Beyond “getting drugs into bodies”: social science perspectives on pre-exposure prophylaxis for HIV , 2015, Journal of the International AIDS Society.

[11]  R. Macklin,et al.  Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access , 2015, Journal of the International AIDS Society.

[12]  W. Heneine,et al.  Cabotegravir long-acting for HIV-1 prevention , 2015, Current opinion in HIV and AIDS.

[13]  K. Mayer,et al.  PrEP implementation: moving from trials to policy and practice , 2015, Journal of the International AIDS Society.

[14]  Frederick Albert Matsen IV,et al.  Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. , 2015, The Journal of infectious diseases.

[15]  J. Baeten,et al.  Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. , 2015, JAMA internal medicine.

[16]  R. Baggaley,et al.  Young key populations and HIV: a special emphasis and consideration in the new WHO Consolidated Guidelines on HIV Prevention, Diagnosis, Treatment and Care for Key Populations , 2015, Journal of the International AIDS Society.

[17]  Megha L Mehrotra,et al.  Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. , 2014, The Lancet. Infectious diseases.

[18]  David R. Holtgrave,et al.  HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel. , 2014, JAMA.

[19]  K. Mayer,et al.  HIV Providers’ Perceived Barriers and Facilitators to Implementing Pre-exposure Prophylaxis in Care Settings: A Qualitative Study , 2014, AIDS and Behavior.

[20]  Megha L Mehrotra,et al.  HIV-1 Drug Resistance in the iPrEx Preexposure Prophylaxis Trial , 2014, The Journal of infectious diseases.

[21]  P. Polgreen,et al.  Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  M. Mimiaga,et al.  Suboptimal awareness and comprehension of published preexposure prophylaxis efficacy results among physicians in Massachusetts , 2014, AIDS care.

[23]  J. Lama,et al.  Provider attitudes toward oral preexposure prophylaxis for HIV prevention among high-risk men who have sex with men in Lima, Peru. , 2014, AIDS research and human retroviruses.

[24]  D. Glidden,et al.  No Evidence of Sexual Risk Compensation in the iPrEx Trial of Daily Oral HIV Preexposure Prophylaxis , 2013, PloS one.

[25]  David M. Tellalian,et al.  Pre-exposure prophylaxis (PrEP) for HIV infection: results of a survey of HIV healthcare providers evaluating their knowledge, attitudes, and prescribing practices. , 2013, AIDS patient care and STDs.

[26]  L. Grohskopf,et al.  Sexual Risk Behavior Among HIV-Uninfected Men Who Have Sex With Men Participating in a Tenofovir Preexposure Prophylaxis Randomized Trial in the United States , 2013, Journal of acquired immune deficiency syndromes.

[27]  C. Hendrix,et al.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial , 2013, The Lancet.

[28]  G. Ippolito,et al.  Attitude towards antiretroviral pre-exposure prophylaxis (PrEP) prescription among HIV specialists , 2013, BMC Infectious Diseases.

[29]  Ashley A. Eggman,et al.  Cost–effectiveness of pre-exposure prophylaxis for HIV: a review , 2012, Current opinion in HIV and AIDS.

[30]  K. Mayer,et al.  Engaging healthcare providers to implement HIV pre-exposure prophylaxis , 2012, Current opinion in HIV and AIDS.

[31]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[32]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[33]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[34]  M. Mimiaga,et al.  Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention. , 2012, AIDS patient care and STDs.

[35]  W. Duffus,et al.  Preexposure Prophylaxis for HIV Infection: Healthcare Providers’ Knowledge, Perception, and Willingness to Adopt Future Implementation in the Southern US , 2012, Southern medical journal.

[36]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[37]  J. Baeten,et al.  Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. , 2008, The Journal of infectious diseases.

[38]  K. Holmes,et al.  Sentinel Surveillance of Sexually Transmitted Infections/HIV and Risk Behaviors in Vulnerable Populations in 5 Central American Countries , 2007, Journal of acquired immune deficiency syndromes.

[39]  D. Fleming,et al.  From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. , 1999, Sexually transmitted infections.